Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival

Affiliations

• ¹ Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, Florida, USA.
• ² Division of Hematology and Medical Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
• ³ Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
• ⁴ Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
• ⁵ Section of Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA.
• ⁶ Robert H. Lurie Comprehensive Cancer Center, Northwestern Hospital, Chicago, Illinois, USA.
• ⁷ Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
• ⁸ Department of Internal Medicine, Mount Sinai Health System, New York, USA.
• ⁹ Department of Hematology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
• ¹⁰ Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
• ¹¹ Division of Hematology and Oncology, Jefferson University Hospital, Philadelphia, Pennsylvania, USA.